These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36452015)

  • 21. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sublingual immunotherapy for asthma.
    Normansell R; Kew KM; Bridgman AL
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011293. PubMed ID: 26315994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study.
    Ras L; de Groot H; Stengs CH; van Weissenbruch R
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):52-58.e2. PubMed ID: 26596408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are convergence lines associated with high asthma presentation days? A case-control study in Melbourne, Australia.
    Bannister T; Csutoros D; Arnold AL; Black J; Feren G; Russell R; Watson A; Williams S; Silver JD; Hughes N
    Sci Total Environ; 2020 Oct; 737():140263. PubMed ID: 32783854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study.
    Florido-López JF; Andreu-Balaguer C; Escudero C; Seoane-Rodríguez M; Hernández M; Navarro-Seisdedos LÁ; Torrecillas-Toro M; Anton-Girones M; Herrero-Lifona L; Brugaletta D; Macías J; Pineda R; Lara MÁ; López-Caballero J; Rojas MJ
    World Allergy Organ J; 2020 Dec; 13(12):100487. PubMed ID: 33376572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of the 21 November 2016 epidemic thunderstorm asthma event on general practice clinics in metropolitan Melbourne, Australia.
    Hughes N; Arnold AL; Brazenor C; Mulvenna V; Csutoros D
    Aust J Gen Pract; 2022 Mar; 51(3):159-165. PubMed ID: 35224587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen.
    Marogna M; Spadolini I; Massolo A; Berra D; Zanon P; Chiodini E; Canonica GW; Passalacqua G
    Ann Allergy Asthma Immunol; 2009 Jan; 102(1):69-75. PubMed ID: 19205289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of allergen-environment interactions in epidemic thunderstorm asthma.
    Hughes KM; Price D; Suphioglu C
    Ther Adv Respir Dis; 2022; 16():17534666221099733. PubMed ID: 35603956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of non-grass pollens respiratory allergies in Italy and effects of specific sublingual immunotherapy: The Rainbow Trial, a multicentre 3-year prospective observational study.
    Milani M; Pecora S;
    Eur Ann Allergy Clin Immunol; 2011 Aug; 43(4):111-6. PubMed ID: 21980798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study.
    Shah-Hosseini K; Krudewig EM; Hadler M; Karagiannis E; Mösges R
    Adv Ther; 2017 Jun; 34(6):1382-1397. PubMed ID: 28455783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children multicenter trial.
    Acquistapace F; Agostinis F; Castella V; Kantar A; Novembre E; Perrone MR; Pietrasanta M; Sambugaro R; Milani M
    Pediatr Allergy Immunol; 2009 Nov; 20(7):660-4. PubMed ID: 19320852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis.
    Köberlein J; Mösges R
    Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The efficacy of sublingual specific immunotherapy in children with allergic rhinitis].
    Li P; Fa M; Huang ZH; Xie LS; Xu Y; Chen WB; Zhang JY; Zhang XR; Zhu Z; Li Q
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 30(7):546-551. PubMed ID: 29871066
    [No Abstract]   [Full Text] [Related]  

  • 34. Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR study.
    Douglass JA; Lodge C; Chan S; Doherty A; Tan JA; Jin C; Stewart A; Southcott AM; Gillman A; Lee J; Csutoros D; Hannan L; Ruane L; Barnes S; Irving L; Harun NS; Lachapelle P; Spriggs K; Sutherland M; See K; McDonald CF; Conron M; Radhakrishna N; Worsnop C; Johnston FH; Davies JM; Bryant V; Iles L; Ranson D; Spanos P; Vicendese D; Lowe A; Newbigin EJ; Bardin P; Dharmage S
    J Allergy Clin Immunol; 2022 May; 149(5):1607-1616. PubMed ID: 34774618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How does the efficacy and safety of Oralair(®) compare to other products on the market?
    Larenas-Linnemann D
    Ther Clin Risk Manag; 2016; 12():831-50. PubMed ID: 27313458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review.
    Didier A; Bons B
    Expert Opin Drug Saf; 2015 May; 14(5):777-88. PubMed ID: 25732009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admission.
    Hew M; Lee J; Susanto NH; Prasad S; Bardin PG; Barnes S; Ruane L; Southcott AM; Gillman A; Young A; Rangamuwa K; O'Hehir RE; McDonald C; Sutherland M; Conron M; Matthews S; Harun NS; Lachapelle P; Douglass JA; Irving L; Langton D; Mann J; Erbas B; Thien F
    Allergy; 2019 Jan; 74(1):122-130. PubMed ID: 30243030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis.
    Devillier P; Wahn U; Zielen S; Heinrich J
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1199-1206. PubMed ID: 29072507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.